BG Medicine Announces Data Analyses Presented at American Heart Association Meeting

BG Medicine Announces Data Analyses Presented at American Heart Association Meeting

November 9, 2012

WALTHAM, Mass., Nov 9, 2012 (GlobeNewswire via COMTEX) -- BG Medicine Inc., a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that results of retrospective analyses of the BioImage Study cohort were presented this week at the American Heart Association (AHA) Scientific Sessions 2012 in Los Angeles. These presentations resulted from research sponsored by the company and included data on the CardioSCORE(TM) test, a proprietary blood test currently being developed by the company.

Visterra Secures Financing from Gates Foundation and Omega to Close $26M Series A Financing

Visterra Secures Financing from Gates Foundation and Omega to Close $26M Series A Financing

November 9, 2012

New investors join existing investors to expand Series A with $13M in new funding

The Boston Globe Names Black Duck a Top Place To Work in 2012

The Boston Globe Names Black Duck a Top Place To Work in 2012

November 5, 2012

BURLINGTON, MA, November 5, 2012 – Black Duck, the trusted partner for open source software adoption, management and governance, has been named a Top Place to Work in Massachusetts in the 2012 employee-based survey from The Boston Globe.

BG Medicine to Highlight Role of Galectin-3 Testing in Reducing Unplanned Hospital Readmissions at the 2012 American Heart Association (AHA) Scientific Sessions

BG Medicine to Highlight Role of Galectin-3 Testing in Reducing Unplanned Hospital Readmissions at the 2012 American Heart Association (AHA) Scientific Sessions

November 5, 2012

WALTHAM, Mass.

Ensemble Therapeutics and Boehringer Ingelheim Initiate Collaboration to Discover Macrocycle Drug Candidates

Ensemble Therapeutics and Boehringer Ingelheim Initiate Collaboration to Discover Macrocycle Drug Candidates

November 1, 2012

Collaboration to deploy Ensemble's innovative platform to discover small molecule drug candidates for Boehringer Ingelheim's targets

CAMBRIDGE, Mass., Nov 01, 2012 (BUSINESS WIRE) -- Ensemble Therapeutics today announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP

Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP

October 25, 2012

Avedro to hold exclusive license to broad iontophoresis patent portfolio

WikiCell Designs’ Edible Food and Beverage Packaging Receives Prestigious SIAL Global Food Industry Award

WikiCell Designs’ Edible Food and Beverage Packaging Receives Prestigious SIAL Global Food Industry Award

October 22, 2012

LS9 Selected as a Top 10 Venture-Backed Green Company by The Wall Street Journal

LS9 Selected as a Top 10 Venture-Backed Green Company by The Wall Street Journal

October 19, 2012

(GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced that the The Wall Street Journal selected the Company as one of the 2012 Top 10 Venture-Backed Green Companies.

BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer

BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer

October 18, 2012

WALTHAM, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has appointed Charles H. Abdalian, Jr., as the company's Executive Vice President, Chief Financial Officer. Mr.

Joule, LS9 and Novomer Named to the Global Cleantech 100 2012

Joule, LS9 and Novomer Named to the Global Cleantech 100 2012

October 17, 2012

Welcome to the Global Cleantech 100 2012

The Global Cleantech 100 represents innovation and highlights the companies most likely to make a significant market impact in the next 5-10 years